Artículos de revistas sobre el tema "Abstract Targeted radionuclide therapy (TRT)"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Abstract Targeted radionuclide therapy (TRT)".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers et al. "Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.
Kerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin et al. "Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.
Pal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, Brian Sanders, Anna Plechaty, Owee Kirpekar, Mircea Podar y Sandra M. Davern. "Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.
Adhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan M. Minnix et al. "Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.
Kerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, David Adam, Maria Powers et al. "Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.
Adhikarla, Vikram, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jeffrey Y. Wong et al. "Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.
Ruder, Samuel, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos et al. "Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.
Sheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, Joseph J. Grudzinski, David Adam, Maria Powers, Raghava N. Sriramaneni et al. "Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.
Vorontsova, M., T. Karmakova, A. Pankratov y A. Kaprin. "Current Trends in Targeted Radionuclide Therapy Development". Medical Radiology and radiation safety 66, n.º 6 (17 de diciembre de 2021): 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.
van der Wal, Bart C. H. y Ekaterina Dadachova. "Targeted Radionuclide Therapy of Cancer and Infections". International Journal of Molecular Sciences 24, n.º 10 (22 de mayo de 2023): 9081. http://dx.doi.org/10.3390/ijms24109081.
Metcalf, Julie, Alexander Nielsen, Suma Prabhu, Nicole Robinson, Sarah Marinacci, Natalie Grinshtein, Brigitte L. Theriault et al. "Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models". Cancer Research 83, n.º 8_Supplement (14 de abril de 2023): LB313. http://dx.doi.org/10.1158/1538-7445.am2023-lb313.
Kerr, Caroline P., Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert y Zachary S. Morris. "Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment". Pharmaceutics 15, n.º 1 (30 de diciembre de 2022): 128. http://dx.doi.org/10.3390/pharmaceutics15010128.
Obata, Honoka, Mikako Ogawa y Michael R. Zalutsky. "DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy". Pharmaceutics 15, n.º 7 (11 de julio de 2023): 1926. http://dx.doi.org/10.3390/pharmaceutics15071926.
Li, Mengshi, Edwin A. Sagastume, Dongyoul Lee, Daniel McAlister, Anthony J. DeGraffenreid, Keith R. Olewine, Stephen Graves et al. "203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer". Current Medicinal Chemistry 27, n.º 41 (8 de diciembre de 2020): 7003–31. http://dx.doi.org/10.2174/0929867327999200727190423.
Adhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan Minnix et al. "A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy". Cancers 13, n.º 20 (15 de octubre de 2021): 5171. http://dx.doi.org/10.3390/cancers13205171.
Malcolm, Javian, Nadia Falzone, Boon Lee y Katherine Vallis. "Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response". Cancers 11, n.º 2 (25 de febrero de 2019): 268. http://dx.doi.org/10.3390/cancers11020268.
Ruigrok, Eline A. M., Wytske M. van Weerden, Julie Nonnekens y Marion de Jong. "The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research". Pharmaceutics 11, n.º 11 (29 de octubre de 2019): 560. http://dx.doi.org/10.3390/pharmaceutics11110560.
Müller, Cristina, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen y Roger Schibli. "Targeted Radiotherapeutics from 'Bench-to-Bedside'". CHIMIA International Journal for Chemistry 74, n.º 12 (23 de diciembre de 2020): 939–45. http://dx.doi.org/10.2533/chimia.2020.939.
Patel, Ravi B., Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe et al. "Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade". Science Translational Medicine 13, n.º 602 (14 de julio de 2021): eabb3631. http://dx.doi.org/10.1126/scitranslmed.abb3631.
Sun, M., C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos et al. "1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT". Annals of Oncology 34 (octubre de 2023): S987. http://dx.doi.org/10.1016/j.annonc.2023.09.2770.
Spoormans, Kaat, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert y Michel Koole. "A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)". Pharmaceutics 14, n.º 10 (22 de septiembre de 2022): 2007. http://dx.doi.org/10.3390/pharmaceutics14102007.
Aprile, Carlo, Onelio Geatti, Letizia Canziani y Lorenzo Lodola. "Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”". Current Issues in Molecular Biology 46, n.º 3 (13 de marzo de 2024): 2398–401. http://dx.doi.org/10.3390/cimb46030152.
Funeh, Cyprine Neba, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D’Huyvetter y Nick Devoogdt. "Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy". Pharmaceutics 15, n.º 5 (30 de abril de 2023): 1378. http://dx.doi.org/10.3390/pharmaceutics15051378.
Potluri, Hemanth, Carolina Ferreira, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Jamey Weichert y Douglas McNeel. "594 Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A624. http://dx.doi.org/10.1136/jitc-2021-sitc2021.594.
Delpassand, Ebrahim S., Mohammad Jawed Hashmi, Julia Kazakin, Omer Nawaz, Gabriella Garufi, Joanne Schindler y Luke Nordquist. "Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)". Cancer Research 84, n.º 7_Supplement (5 de abril de 2024): CT224. http://dx.doi.org/10.1158/1538-7445.am2024-ct224.
Ruigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden y Julie Nonnekens. "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment". International Journal of Molecular Sciences 23, n.º 14 (21 de julio de 2022): 8037. http://dx.doi.org/10.3390/ijms23148037.
Williams, L. "WE-E-214-03: Biology and Physiology of Targeted Radionuclide Therapy (TRT)". Medical Physics 38, n.º 6Part33 (junio de 2011): 3822. http://dx.doi.org/10.1118/1.3613392.
Speer, T. W., P. Bernhardt, B. Bednarz, P. Harari, J. Saker y B. Thomadsen. "Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)". International Journal of Radiation Oncology*Biology*Physics 84, n.º 3 (noviembre de 2012): S709. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1898.
Potluri, Hemanth K., Carolina A. Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ohyun Kwon et al. "Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors". Journal for ImmunoTherapy of Cancer 10, n.º 8 (agosto de 2022): e005060. http://dx.doi.org/10.1136/jitc-2022-005060.
Akil, Hussein, Mercedes Quintana, Jérémy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux et al. "Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma". Cancers 13, n.º 6 (20 de marzo de 2021): 1421. http://dx.doi.org/10.3390/cancers13061421.
Müller, Cristina, Maria De Prado Leal, Marco D. Dominietto, Christoph A. Umbricht, Sairos Safai, Rosalind L. Perrin, Martina Egloff et al. "Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute". Pharmaceutics 11, n.º 9 (2 de septiembre de 2019): 450. http://dx.doi.org/10.3390/pharmaceutics11090450.
Mdanda, Sipho, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge y Jan Rijn Zeevaart. "Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review". Pharmaceutics 15, n.º 6 (13 de junio de 2023): 1719. http://dx.doi.org/10.3390/pharmaceutics15061719.
Sun, M., C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A. M. Molina et al. "1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)". Annals of Oncology 33 (septiembre de 2022): S1179. http://dx.doi.org/10.1016/j.annonc.2022.07.1522.
de Roode, Kim E., Lieke Joosten y Martin Behe. "Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands". Pharmaceuticals 17, n.º 2 (16 de febrero de 2024): 256. http://dx.doi.org/10.3390/ph17020256.
Cortiana, Viviana, Jade Gambill, Harshal Chorya, Diksha Mahendru, Fabiha Amin, Chandler H. Park y Yan Leyfman. "PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa". Cancers 16, n.º 10 (11 de mayo de 2024): 1833. http://dx.doi.org/10.3390/cancers16101833.
Sun, Michael, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander y Scott T. Tagawa. "Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 5055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5055.
Thomas, Joseph Earl, Jones T. Nauseef, Michael Philip Sun, Amie Patel, Angela Tan, Mahelia Bissassar, Jyothi Manohar et al. "Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center." Journal of Clinical Oncology 41, n.º 6_suppl (20 de febrero de 2023): 36. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.36.
Sodji, Quaovi H., Matthew H. Forsberg, Dan Cappabianca, Caroline P. Kerr, Lauren Sarko, Amanda Shea, David P. Adam et al. "Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions". Cancers 16, n.º 1 (30 de diciembre de 2023): 191. http://dx.doi.org/10.3390/cancers16010191.
Li, Mengshi, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J. Baumhover, Brenna M. Marks, Edwin A. Sagastume et al. "Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma". Cancers 13, n.º 15 (22 de julio de 2021): 3676. http://dx.doi.org/10.3390/cancers13153676.
Everix, Liesbeth, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde y Julie Bolcaen. "Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma". Cancers 14, n.º 7 (3 de abril de 2022): 1821. http://dx.doi.org/10.3390/cancers14071821.
Magee, Kara, Ian R. Marsh, Michelle M. Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ilene D. Kurzman et al. "Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting". PLOS ONE 16, n.º 8 (12 de agosto de 2021): e0255798. http://dx.doi.org/10.1371/journal.pone.0255798.
Muralidhar, Anusha, Reinier Hernandez, Zachary S. Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P. Weichert y Douglas G. McNeel. "Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors". Journal for ImmunoTherapy of Cancer 12, n.º 4 (abril de 2024): e008760. http://dx.doi.org/10.1136/jitc-2023-008760.
Métivier, Cassandra, Patricia Le Saëc, Joëlle Gaschet, Catherine Chauvet, Séverine Marionneau-Lambot, Peter O. Hofgaard, Bjarne Bogen et al. "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma". Pharmaceutics 15, n.º 7 (25 de junio de 2023): 1817. http://dx.doi.org/10.3390/pharmaceutics15071817.
Vlachostergios, Panagiotis J., Muhammad Junaid Niaz, Seyed Ali Mosallaie, Paul J. Christos, Amy Hackett, Joseph R. Osborne, Yuliya Jhanwar et al. "Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): 5013. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5013.
Reiner, Dora, Matthias Blaickner y Frank Rattay. "Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated withMCNP5". Medical Physics 36, n.º 11 (2 de octubre de 2009): 4890–96. http://dx.doi.org/10.1118/1.3231995.
Sun, Michael, Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez, Amie Patel et al. "Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 39, n.º 6_suppl (20 de febrero de 2021): 158. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.158.
Fernandes, Célia, Elisa Palma, Francisco Silva, Ana Belchior, Catarina I. G. Pinto, Joana F. Guerreiro, Hugo M. Botelho, Filipa Mendes, Paula Raposinho y António Paulo. "Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus". International Journal of Molecular Sciences 23, n.º 13 (29 de junio de 2022): 7238. http://dx.doi.org/10.3390/ijms23137238.
Rao, Yi, Tara Viray, Kurt Gehlsen, Matt Harris, Lachlan McInnes, Olufolake Majekodunmi y Jason Lewis. "Abstract 6038: Copper-67 based targeted radiotherapy primes immunologically cold PDAC for immunotherapy". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 6038. http://dx.doi.org/10.1158/1538-7445.am2024-6038.
Ruder, Samuel Francis, Michael Philip Sun, Charlene Thomas, Ana M. Molina, Jones T. Nauseef, Joseph Osborne, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander y Scott T. Tagawa. "Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector." Journal of Clinical Oncology 42, n.º 4_suppl (1 de febrero de 2024): 161. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.161.
Sanchez-Garcia, Manuel, Isabelle Gardin, Rachida Lebtahi y Arnaud Dieudonné. "A new approach for dose calculation in targeted radionuclide therapy (TRT) based on collapsed cone superposition: validation with90Y". Physics in Medicine and Biology 59, n.º 17 (6 de agosto de 2014): 4769–84. http://dx.doi.org/10.1088/0031-9155/59/17/4769.